| scholarly article | Q13442814 |
| P50 | author | Barbara Ensoli | Q21255143 |
| Marjorie Robert-Guroff | Q30651738 | ||
| Norman L. Letvin | Q98917684 | ||
| Birgit Korioth-Schmitz | Q57016730 | ||
| P2093 | author name string | V S Kalyanaraman | |
| David C Montefiori | |||
| Aurelio Cafaro | |||
| Thorsten Demberg | |||
| Richard Grant | |||
| David Venzon | |||
| Dilani Dombagoda | |||
| L Jean Patterson | |||
| Ranajit Pal | |||
| Eun Mi Lee | |||
| Irene Kalisz | |||
| Kay Larsen | |||
| Adam Buzby | |||
| Megan J Heath | |||
| Ruth H Florese | |||
| P2860 | cites work | Of mice and not men: differences between mouse and human immunology | Q28246229 |
| The multiple functions of HIV-1 Tat: proliferation versus apoptosis | Q28271014 | ||
| Modifications in the human T cell proteome induced by intracellular HIV-1 Tat protein expression | Q28301068 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants | Q30976921 | ||
| Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein | Q31135334 | ||
| Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains | Q33785321 | ||
| Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection | Q33834852 | ||
| Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies | Q33911986 | ||
| Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys | Q33984182 | ||
| Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses | Q34105993 | ||
| Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat. | Q34269140 | ||
| Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 | Q64378954 | ||
| Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals | Q73520478 | ||
| Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine | Q77296129 | ||
| Comparative analysis of HIV-1 Tat variants | Q81171039 | ||
| Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection | Q34358162 | ||
| Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine. | Q34488930 | ||
| Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells | Q35024276 | ||
| Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques | Q35114827 | ||
| Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys | Q35123128 | ||
| Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. | Q35182076 | ||
| Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation | Q35849709 | ||
| An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge | Q35898573 | ||
| Recent advances in the development of HIV-1 Tat-based vaccines | Q35949947 | ||
| HIV vaccines: new frontiers in vaccine development | Q36534852 | ||
| Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation | Q36639380 | ||
| Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting | Q36954239 | ||
| Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses | Q37285535 | ||
| Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins | Q37742938 | ||
| Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein | Q39683362 | ||
| The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection. | Q39805021 | ||
| Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells | Q40274328 | ||
| HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity | Q40517749 | ||
| Tat-mediated protein delivery can facilitate MHC class I presentation of antigens | Q41160245 | ||
| Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. | Q41335848 | ||
| Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein | Q41349382 | ||
| Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. | Q41925734 | ||
| The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters | Q43671904 | ||
| Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques | Q43953620 | ||
| Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes | Q44666320 | ||
| Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). | Q45012988 | ||
| Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides | Q45231619 | ||
| Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans | Q45710857 | ||
| Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology | Q45743923 | ||
| Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. | Q45761033 | ||
| The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes | Q45869894 | ||
| HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers | Q46830857 | ||
| Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients | Q47216468 | ||
| Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. | Q51998598 | ||
| Maintenance of serological memory by polyclonal activation of human memory B cells. | Q52008907 | ||
| An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. | Q52840793 | ||
| Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia | Q57075698 | ||
| Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine | Q59511395 | ||
| Candidate HIV-1 Tat vaccine development: from basic science to clinical trials | Q59647820 | ||
| Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag | Q61641083 | ||
| Dual role of HIV Tat in regulation of apoptosis in T cells | Q63351479 | ||
| Full-length HIV-1 Tat protein necessary for a vaccine | Q63384219 | ||
| Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses | Q64377680 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Adenoviridae | Q193447 |
| P304 | page(s) | 3414-3427 | |
| P577 | publication date | 2007-01-17 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques | |
| P478 | volume | 81 |
| Q37054470 | A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice |
| Q44280840 | A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. |
| Q92906228 | Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease |
| Q36667821 | Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS |
| Q36071414 | Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector. |
| Q34148683 | Challenges in HIV Vaccine Research for Treatment and Prevention |
| Q34616275 | Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques |
| Q36961218 | Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection |
| Q64375028 | Comparison of systemic and mucosal immunization with replicating Single cycle Adenoviruses |
| Q33872445 | Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains |
| Q37347813 | Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. |
| Q38533881 | Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine |
| Q42100401 | Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates |
| Q64374898 | Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques |
| Q35021632 | Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors |
| Q43942291 | Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions |
| Q38728732 | Future Prospects for the Development of Cost-Effective Adenovirus Vaccines |
| Q89552900 | Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope |
| Q34485178 | Genomic Analysis Reveals Pre- and Postchallenge Differences in a Rhesus Macaque AIDS Vaccine Trial: Insights into Mechanisms of Vaccine Efficacy |
| Q35883997 | HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost |
| Q30372278 | HIV immunopathogenesis and strategies for intervention. |
| Q37341025 | HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies |
| Q35032794 | HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques |
| Q30381447 | HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. |
| Q34477471 | HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies |
| Q36986644 | HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial |
| Q42286975 | Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses |
| Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
| Q33915690 | Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses |
| Q34016756 | IIIa deleted adenovirus as a single-cycle genome replicating vector |
| Q37096865 | Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques |
| Q37361294 | Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques |
| Q42284964 | Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers |
| Q36946545 | Macaques vaccinated with live-attenuated SIV control replication of heterologous virus |
| Q37627897 | Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine |
| Q22241377 | Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes |
| Q58604129 | Mucosal T helper 17 and T regulatory cell homeostasis correlates with acute SIV viremia and responsiveness to antiretroviral therapy in macaques |
| Q92889493 | Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission |
| Q30375160 | Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. |
| Q36827361 | Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys |
| Q37419985 | Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses |
| Q33966586 | Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques |
| Q38652858 | Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo |
| Q26861148 | Nonhuman primate models for HIV/AIDS vaccine development |
| Q47112156 | Novel Concepts for HIV Vaccine Vector Design |
| Q30378897 | Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. |
| Q57078036 | Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine |
| Q35160124 | Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges |
| Q36276936 | Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid |
| Q34117097 | Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies |
| Q64376800 | Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques |
| Q56993265 | Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development |
| Q35867976 | Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac2 |
| Q36464587 | Replicating and non-replicating viral vectors for vaccine development |
| Q37547763 | Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques |
| Q33898131 | Role of humoral immunity in host defense against HIV. |
| Q36949703 | Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge |
| Q47282517 | Single-cycle adenovirus vectors in the current vaccine landscape |
| Q37640717 | Stable expression of a foreign protein by a replication-competent rubella viral vector |
| Q35141486 | Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory |
| Q30238730 | Survivors Remorse: antibody-mediated protection against HIV-1. |
| Q37297052 | Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge |
| Q37364423 | The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice |
| Q33864926 | The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study |
| Q52592228 | Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection. |
| Q35636394 | Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques |
Search more.